CHCWM – Cancer & Hematology Centers of West Michigan

ALKS 4230-003 (Alkermes Inc. )

ALKS 4230-003 (Alkermes Inc. ) Description:  Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3) Mechanism of Action:  IL2 receptor agonist Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors

AT148002 (ALX Oncology)

AT148002 (ALX Oncology)  Description:   A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Mechanism of Action:  ALX148 is a CD47 blocker. Target Patient Population: High Risk MDS Study Design:  Study Drug will be administered IV every 2 or 4 weeks.  Combination drug, Azacitidine given as would

ALPN-202-NEON-1 (Alpine Immune Sciences)

ALPN-202 – NEON-1 (Alpine Immune Sciences) Description:  An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)  Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator. Target Patient Population: Currently in expansion for Melanoma, Renal cell  and PDL1 positive cancers only Study Design: Study drug is administered IV every 1 or 3 weeks

AstraZeneca (CAPITELLO-281)

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281) Principal Investigator: Dr. Eric Batts For more information on this trial, read its profile on clinicaltrials.gov here.

AstraZeneca D8151C00001

  A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion For more information on this

AstraZeneca (PACIFIC-9)

  A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9) PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer

AstraZeneca D910DC00001 (EMERALD2)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Principal Investigator: Dr. Manish Sharma For more information on this trial, read its profile on clinicaltrials.gov here.

Genentech (CELESTIMO)

  PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY PI: Dr. Brinker

CPI-0209-01 (Constellation)

CPI-0209-01 (Constellation) Description:   A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors Mechanism of Action:  EZH2  Inhibitor Target Patient Population:  In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial.  Study Design:  Drug is given orally daily.

GSK2857916 (DREAMM5) (GlaxoSmithKline Research)

GSK2857916 (DREAMM5)  (GlaxoSmithKline Research)  Description:  As Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 Mechanism of action:  anti BCMA antibody drug conjugate Target Patient Population:  Multiple Myeloma Study Design:  Study Drug is administered